Skip to main content

Market Overview

Jefferies Highlights A Pair Trade In Pharma: Buy ICON, Hold Tight On INC Research


Jefferies said in a note on Thursday that it's focused on two opposing themes in pharma services, namely slowing outsourcing and revenue growth and consolidation, with the former increasing the need for the latter.

Against this backdrop, the firm highlighted a pair trade in the pharma services sector. Jefferies upgraded shares of ICON PLC (NASDAQ: ICLR) and downgraded shares of INC Research Holdings Inc (NASDAQ: INCR).

See Also: Gates Foundation Deal Opens Things Up For OraSure

Analyst David Windley said feedback from industry sources added credibility to the shift away from full-service outsourcing and to slowing growth. The analyst thinks the M&A theme is trumping slowing growth and that ICON is the best way to play this directly.

Jefferies also updated and increased its price target for its pharma services coverage to reflect sector growth and valuations, relative to the market. The firm feels the valuations of late-state contract research organizations, or CRO appear reasonable, despite the slowing industry growth.

"Our updated PTs better reflect the reality that current multiples are sustainable provided the broader market remains healthy," the firm said.

On specific stocks, Jefferies prefers stocks insulated from Insourcing such as Charles River Laboratories Intl. Inc (NYSE: CRL) and PRA Health Sciences Inc (NASDAQ: PRAH), or with M&A optionality such as ICON. Giving reasons for its shift out of INC Research and into ICON, the firm said INC Research has near term integration risk, while ICON has potential for multiple expansion and also for larger M&A.

ICON Favored Due to Valuation And M&A

Jefferies believes ICON offers a more compelling risk/reward over the next 12 months. The firm noted that shares continues to trade at a group discount. Accordingly, the firm sees solid appreciation potential, as Pfizer Inc. (NYSE: PFE) concentration is reduced, with potentially 45 percent upside with more aggressive M&A.

On the other hand, Jefferies thinks INC Research's recent merger with inventive, though markedly improving its strategic position, brings with it near term integration risk not fully incorporated into shares.

As such, Jefferies upgraded shares of ICON from Hold to Buy, with the price target lifted to $117. Meanwhile, the firm downgraded shares of INC Research to Hold from Buy, but increased the price target to $64.

Latest Ratings for ICLR

May 2021MizuhoMaintainsBuy
Apr 2021Credit SuisseMaintainsOutperform
Apr 2021JefferiesMaintainsBuy

View More Analyst Ratings for ICLR
View the Latest Analyst Ratings


Related Articles (ICLR + INCR)

View Comments and Join the Discussion!

Posted-In: David Windley JefferiesAnalyst Color Upgrades Downgrades Price Target Analyst Ratings Trading Ideas

Latest Ratings

ATUSB of A SecuritiesDowngrades38.0
CNIVertical ResearchUpgrades
LINVertical ResearchUpgrades330.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at